Why AstraZeneca is Investing $15bn in Chinese Manufacturing
AstraZeneca has revealed plans for a US$15bn investment in China through 2030, positioning the country as a central pillar of its global strategy for medicines manufacturing and research and development.
The pharmaceutical giant says the commitment will strengthen its capacity to discover, develop and manufacture new treatments while advancing its broader ambitions for the end of the decade.
The move could also draw on China's scientific expertise, advanced manufacturing infrastructure and expanding healthcare collaboration between China and the UK.
This investment was unveiled during UK Prime Minister Keir Starmer's visit to China.
“Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements,” Mr Starmer says.
“AstraZeneca’s expansion and leadership in China will help the British manufacturer continue to grow - supporting thousands of UK jobs.
“The multi-billion pound investment announced today from AstraZeneca, alongside partnerships from some of our country’s leading universities, furthers research and development in the UK which is helping to power our world class life sciences sector.”
Next-generation treatment
According to AstraZeneca, the investment will significantly bolster its capabilities in advanced modalities, including cell therapy and radioconjugates.
These areas are becoming increasingly important in developing next generation treatments for cancer, haematological conditions and autoimmune diseases.
The investment will span the entire value chain, from drug discovery and clinical development through to large-scale manufacturing, recognising China's advanced science in these areas.
AstraZeneca is also collaborating with leading Chinese biotechs including AbelZeta, CSPC, Harbour BioMed, Jacobio and Syneron Bio, bringing Chinese innovation to global markets through strategic partnerships.
Following its 2024 acquisition of Gracell Biotechnologies, AstraZeneca will become the first global biopharmaceutical company with end-to-end cell therapy capabilities in China.
Pascal Soriot, Chief Executive Officer of AstraZeneca, adds: “Today’s landmark investment of US$15bn begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing and global public health.
“By expanding our capabilities in breakthrough treatments like cell therapy and radioconjugates, we will strengthen our contribution to China’s high-quality development and, most importantly, bring next-generation modalities to patients.”
Cross-border manufacturing partnerships
According to AstraZeneca, the investment will strengthen China-UK collaboration in healthcare innovation, building on existing ecosystem partnerships with the University of Cambridge and collaborators in Beijing.
The company is also working with other major research and financial institutions, including the University of Oxford, the University of Glasgow, King's College London and HSBC, to establish additional cross-border collaborations between leading life sciences ecosystems.
The investment aligns with the goals of Healthy China 2030 and aims to prioritise China's 'Common Health' agenda by expanding prevention, early detection and access to innovative medicines for underserved communities.
China remains AstraZeneca's second largest market and a strategic hub for global innovation.
Since entering the country in 1993, AstraZeneca has introduced more than 40 innovative medicines, with its treatments benefiting 68 million patients in China in 2025 alone.
